Steven Smith, MD
Orthopedic Surgery · North Kansas City, MONPI 1750475836
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,354 of the $3,755 with a category attached, or 62.7%. Arthrex accounts for 63.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $2,734 and has fallen 97.4% since, to $71 in 2025.
Across 39 payments — averaging $96.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$2K
- Stryker$502
- Johnson & Johnson$223
- Amgen$167
- Smith+Nephew$153
- Titan Surgical Group, LLC$71
- plus $256 from 11 others
What the payments were for
- Food & beverage$1,40137%
- Education$2,35463%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 3 | $2,382 |
| Stryker | 5 | $502 |
| Johnson & Johnson | 6 | $223 |
| Amgen | 9 | $167 |
| Smith+Nephew | 2 | $153 |
| Titan Surgical Group, LLC | 1 | $71 |
| Baudax Bio Inc. | 2 | $40 |
| Zimmer Biomet | 2 | $40 |
| Pacira Pharmaceuticals Incorporated | 1 | $29 |
| Davol Inc. | 1 | $26 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Acumed LLC | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Pfizer | 1 | $15 |
| FX Shoulder Solutions, Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$444
- TFN ADVANCED$150
- REAL INTELLIGENCE$141
How this compares
Too few orthopedic surgery providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 183 | $3,424 |
| Oxycodone Hcl | 176 | $996 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 108 | $917 |
| Gabapentin | 171 | $809 |
| Tramadol Hcl | 253 | $735 |
| Meloxicam | 109 | $313 |
| Cephalexin | 69 | $267 |
| Naproxen | 33 | $232 |
| Doxycycline Hyclate | 11 | $92 |
| Methylprednisolone | 12 | $54 |
| Cyclobenzaprine Hcl | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Other orthopedic surgery in North Kansas City
- James ReardonNorth Kansas City$1K
- Leo WhitesideSaint Louis$500K
- Zachary BurnettSaint Louis$56K
- John KrauseChesterfield$7K
- Richard LehmanSaint Louis$5K
- Mitchell RotmanChesterfield$2K
- Daniel MartinSaint Louis$1K
- Hee LeeColumbia$165
- Alan MorrisSaint Louis$0
- Robert MarkensonSaint Louis$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.